Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/III study of MIL62 injection in neuromyelitis optica spectrum disorder
CTR20212995Phase 3Active
- Sponsor
- Mabworks Biotech
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Mabworks Biotech. Started Aug 2022; status: active.
02
Drugs
Bejescin
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20212995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212995.